NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free EDIT Stock Alerts $5.24 -0.11 (-2.06%) (As of 03:29 PM ET) Add Compare Share Share Today's Range$5.11▼$5.2750-Day Range$5.35▼$11.0752-Week Range$5.11▼$11.91Volume1.00 million shsAverage Volume1.82 million shsMarket Capitalization$430.94 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Editas Medicine alerts: Email Address Editas Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside187.4% Upside$15.00 Price TargetShort InterestBearish22.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.52Based on 6 Articles This WeekInsider TradingSelling Shares$924,582 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.61) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.60 out of 5 starsMedical Sector233rd out of 907 stocksBiological Products, Except Diagnostic Industry33rd out of 153 stocks 3.3 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageEditas Medicine has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.81% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Editas Medicine has recently increased by 14.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 71.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.78. Previous Next 2.5 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Editas Medicine this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat Follows17 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 31% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $924,582.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($2.61) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Editas Medicine Stock (NASDAQ:EDIT)Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesApril 24, 2024 | investing.comEditas to present gene editing advancements at ASGCTApril 23, 2024 | americanbankingnews.comFinancial Analysis: Editas Medicine (NASDAQ:EDIT) vs. Outlook Therapeutics (NASDAQ:OTLK)April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 22, 2024 | globenewswire.comEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingApril 21, 2024 | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from BrokeragesApril 18, 2024 | investing.comEditas Medicine Inc (EDIT)April 9, 2024 | finance.yahoo.comDr. Chi Li Joins Curevo Vaccine as Chief Regulatory OfficerMarch 13, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 12, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)March 7, 2024 | fool.com1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.March 6, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)March 4, 2024 | fool.com1 Beaten-Down Stock With 55% Upside, According to Wall StreetMarch 2, 2024 | fool.comWhy Editas Medicine Stock Soared as Much as 42% Higher This WeekMarch 1, 2024 | markets.businessinsider.comStrong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive OptimismFebruary 29, 2024 | markets.businessinsider.comHold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation PotentialFebruary 29, 2024 | finance.yahoo.comQ4 2023 Editas Medicine Inc Earnings CallFebruary 28, 2024 | msn.comEditas Medicine files for mixed shelf offeringFebruary 28, 2024 | marketwatch.comEditas Medicine Shares Rally After Reni-cel Study UpgradeFebruary 28, 2024 | msn.comEditas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32MFebruary 28, 2024 | markets.businessinsider.comHere's what Wall Street expects from Editas Medicine's earnings reportFebruary 28, 2024 | finance.yahoo.comEditas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing TrialsFebruary 28, 2024 | msn.comEditas spikes as Vertex Pharma deal boosts Q4 toplineFebruary 28, 2024 | globenewswire.comEditas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business UpdatesFebruary 27, 2024 | benzinga.comEarnings Outlook For Editas MedicineFebruary 27, 2024 | msn.comEditas Medicine Q4 2023 Earnings PreviewFebruary 24, 2024 | finance.yahoo.comEDIT Mar 2024 7.000 putSee More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees265Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+186.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,220,000.00 Net Margins-196.12% Pretax Margin-196.12% Return on Equity-42.95% Return on Assets-30.49% Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Sales & Book Value Annual Sales$78.12 million Price / Sales5.51 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book1.22Miscellaneous Outstanding Shares82,240,000Free Float80,673,000Market Cap$430.12 million OptionableOptionable Beta2.01 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Gilmore O'Neill M.D. (Age 59)President, CEO & Director Comp: $815.37kDr. Baisong Mei M.D.Ph.D., Senior VP & Chief Medical OfficerDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 70)Co-Founder & Scientific Advisory Board Member Dr. J. Keith Joung M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberMr. Erick J. Lucera C.F.A. (Age 56)CPA, CFO & Executive VP Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific OfficerCristi BarnettCorporate Communications & Investor RelationsMs. Charlene Stern J.D.Ph.D., Executive VP & General CounselMore ExecutivesKey CompetitorsHumacyteNASDAQ:HUMATaysha Gene TherapiesNASDAQ:TSHAC4 TherapeuticsNASDAQ:CCCCAlvotechNYSE:ALVOVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 18,745 shares on 4/24/2024Ownership: 0.069%Los Angeles Capital Management LLCBought 147,883 shares on 4/5/2024Ownership: 0.181%Vanguard Group Inc.Sold 74,351 shares on 3/11/2024Ownership: 10.343%Gilmore Neil O'neillSold 77,824 sharesTotal: $733,102.08 ($9.42/share)Baisong MeiSold 20,327 sharesTotal: $191,480.34 ($9.42/share)View All Insider TransactionsView All Institutional Transactions EDIT Stock Analysis - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price target for 2024? 9 brokerages have issued twelve-month price targets for Editas Medicine's stock. Their EDIT share price targets range from $9.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 187.4% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2024? Editas Medicine's stock was trading at $10.13 at the start of the year. Since then, EDIT stock has decreased by 48.5% and is now trading at $5.22. View the best growth stocks for 2024 here. Are investors shorting Editas Medicine? Editas Medicine saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 18,760,000 shares, an increase of 14.7% from the March 31st total of 16,360,000 shares. Based on an average trading volume of 1,910,000 shares, the days-to-cover ratio is presently 9.8 days. View Editas Medicine's Short Interest. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.29. The company earned $60 million during the quarter, compared to analyst estimates of $4.84 million. Editas Medicine had a negative net margin of 196.12% and a negative trailing twelve-month return on equity of 42.95%. The company's quarterly revenue was up 817.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.88) earnings per share. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Horizon Kinetics Medical ETF (MEDX), AXS Green Alpha ETF (NXTE), WisdomTree BioRevolution Fund (WDNA) and Global X Genomics & Biotechnology ETF (GNOM).iShares Genomics Immunology and Healthcare ETF (IDNA). What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.18%) and Assenagon Asset Management S.A. (0.07%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EDIT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
